Three Innovative Ideas Receive $10,000 Prizes in Patients | Choices | Empowerment Competition

AmgenThe Amgen Foundation and Ashoka's Changemakers today announced three winners for the Patients | Choices | Empowerment competition. Each winner will receive a $10,000 cash prize and was selected by the public for their innovative solutions that empower and elevate patients' voices to improve health outcomes.

Out of 10 finalists, the entries receiving the most votes in the Changemakers.com competition are:

1. CureTogether - Crowdsourced Patient Experience
2. Educating Tuberculosis patients for excellent results
3. SMS Now! A Life Depends on It.

In addition, selected entries may be considered for additional grants totaling up to $1 million from the Amgen Foundation.

"The Patients | Choices | Empowerment winners demonstrate that it is possible to create innovative tools and resources that empower patients and offer collaborative solutions at every stage of healthcare," said Jean Lim, president of the Amgen Foundation. "This competition has helped to build a global community of innovators who are working to ensure that patients have an active role in their personal healthcare. We look forward to reviewing the entries to identify sustainable solutions that both the Amgen Foundation and other interested funders can support."

The winning entries are crowdsourcing quantitative data to help patients make more informed choices about their healthcare; removing the stigma around tuberculosis and encouraging and supporting treatment; and utilizing the internet and mobile technology to connect volunteer blood donors with patients. All of these innovations demonstrate global solutions.

"The Patients | Choices | Empowermentcompetition uncovered ideas that help patients makedecisions with confidence and clarity,in concertwithpeople who careand can help," said Diana Wells, president of Ashoka. "We are so pleased with the online community that joined the Changemakers platform, voted, and shared their feedback on these innovative solutions. We are also incredibly thankful to our expert judges and commentators who contributed to the creation of a rich, global dialogue on the important issues that ultimately resulted in the selection of three outstanding entries."

In addition to the $10,000 cash prizes, the three Patients | Choices | Empowermentcompetition winners will be featured on Changemakers.com as innovative ideas for empowering the patient and providing avenues for informed decisions.

About Ashoka's Changemakers
Ashoka's Changemakers is a community of action that connects social entrepreneurs around the globe to share ideas, inspire, and mentor each other. Through its online collaborative competitions and open-source process, Changemakers.com is one of the world's most robust spaces for launching, discussing, and funding ideas to solve the world's most pressing social problems. Changemakers builds on Ashoka's three decade history and belief that we all have the ability to be a Changemaker. www.Changemakers.com

About the Amgen Foundation
The Amgen Foundation seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live and work. Since 1991, the Foundation has made more than $140 million in grants to nonprofit organizations throughout the United States, Puerto Rico, and Europe that impact society in inspiring and innovative ways, and those that provide disaster relief efforts both domestically and internationally.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]